Temporal trends in characteristics and outcomes of patients undergoing percutaneous mitral valve repair

doi:10.4330/wjc.v17.i12.110450

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

This Article

(35)

(49)

(0)

(9)

(577)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Cardiol. Dec 26, 2025; 17(12): 110450
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.110450

Table 2 Hospital presentation and echocardiographic parameters, mean ±SD, n (%)

Variable	Pooled real-life variables	EVEREST program, population size	EVEREST vs pooled variable, MD or OR (95%CI)	COAPT trial, population size	COAPT vs pooled variable, MD or OR (95%CI)	MITRA-FR trial, population size	MITRA-FR vs pooled variable, MD or OR (95%CI)
First five-year period
NYHA II	10.5 (7.2-14.2); I² = 84	107/615 (17.4)	1.60 (1.26-2.02)	129/302 (42.7)	5.66 (4.40-7.28)	56/152 (36.8)	4.43 (3.13-6.26)
NYHA III	24.9 (18.3-32.0); I² = 79	387/615 (62.9)	4.13 (3.41-5.00)	154/302 (50.9)	2.53 (1.98-3.24)	82/152 (53.9)	2.85 (2.04-3.98)
NYHA IV	23.3 (18.9-27.9); I² = 84	108/615 (17.6)	0.77 (0.62-0.96)	18/302 (5.9)	0.23 (0.14-0.37)	14/152 (9.2)	0.37 (0.21-0.64)
NYHA III/IV	89.8 (86.2-92.9); I² = 87	495/615 (80.5)	0.60 (0.48-0.75)	172/302 (57.0)	0.19 (0.15-0.25)	96/152 (63.1)	0.25 (0.18-0.35)
MR grade 3+	40.5% (31.3-50.0); I² = 97	355/616 (58.1)	2.21 (1.86-2.63)	148/302 (49.0)	0.95 (0.74-1.22)	46/123 (37.4)	0.97 (0.67-1.41)
MR grade 4+	60.8% (52.4-68.9); I² = 96	139/616 (22.7)	0.17 (0.14-0.20)	154/302 (51.0)	0.59 (0.47-0.75)	76/123 (61.8)	0.92 (0.64-1.34)
LVEDV (ml)	177.34 ± 1.22; Q = 7.73	162.2 ± 52.8 (558)	-15.10 (-19.48 to -10.72)	194.4 ± 69.2 (n = 302)	17.10 (9.30-24.90)	258.8 ± 71.1¹ (n = 152)	80.70 (69.40-92.00)
LVEF (%)	25.81 ± 0.22; Q = 50.71	43.2 ± 11.7 (558)	17.40 (16.43-18.37)	31.3 ± 9.1 (n = 302)	5.50 (4.47-6.53)	33.3 ± 6.5 (n = 152)	7.50 (6.47-8.53)
Second five-year period
NYHA II	11.2 (5.4-18.6); I² = 93	107/615 (17.4)	1.11 (0.87-1.41)	129/302 (42.7)	3.93 (3.03-5.09)	56/152 (36.8)	3.07 (2.16-4.37)
NYHA III	68.9 (60.4-76.8); I² = 90	387/615 (62.9)	0.88 (0.72-1.08)	154/302 (50.9)	0.54 (0.42-0.70)	82/152 (53.9)	0.61 (0.43-0.85)
NYHA IV	21.8 (14.6-29.9); I² = 86	108/615 (17.6)	0.69 (0.54-0.89)	18/302 (5.9)	0.21 (0.13-0.34)	14/152 (9.2)	0.33 (0.19-0.58)
NYHA III/IV	90.6 (84.1-95.7); I² = 94	495/615 (80.5)	0.69 (0.55-0.87)	172/302 (57.0)	0.22 (0.17-0.29)	96/152 (63.1)	0.29 (0.20-0.41)
MR grade 3+	57.3 (37.6-75.8); I² = 98	355/616 (58.1)	2.27 (1.90-2.73)	148/302 (49.0)	1.61 (1.26-2.04)	46/123 (37.4)	1.00 (0.69-1.45)
MR grade 4+	57 (36.3-76.5); I² = 98	139/616 (22.7)	0.15 (0.13-0.19)	154/302 (51.0)	0.55 (0.43-0.70)	76/123 (61.8)	0.86 (0.59-1.25)
LVEDV (ml)	155.38 ± 0.31; Q = 8.26	162.2 ± 52.8 (558)	6.80 (2.42-11.18)	194.4 ± 69.2 (n = 302)	39.00 (31.20-46.80)	258.8 ± 71.1¹ (n = 152)	102.60 (91.30-113.90)
LVEF	35.15 ± 0.17; Q = 15.97	43.2 ± 11.7 (558)	8.00 (7.03-8.97)	31.3 ± 9.1 (n = 302)	-3.90 (-4.93, -2.87)	33.3 ± 6.5 (n = 152)	-1.90 (-2.93 to -0.87)

¹136.2 ± 37.4 mL/m² converted to mL using 1.9 m².

EVEREST: Endovascular Valve Edge-to-Edge Repair Study; COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation; MITRA-FR: Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation; 95%CI: 95% confidence interval; ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; ICD: Implantable cardioverter-defibrillator; MD: Mean difference; OR: Odds ratio; LVEF: Left ventricular ejection fraction; LVEDV: Left ventricular end-diastolic volume; MR: Mitral regurgitation; NYHA: New York Heart Association.

Full Size Table

Citation: Kaddoura R, Dakhil Z, Al-Badriyeh D, Abushanab D, Rafie I, Al-Hijji M. Temporal trends in characteristics and outcomes of patients undergoing percutaneous mitral valve repair. World J Cardiol 2025; 17(12): 110450
URL: https://www.wjgnet.com/1949-8462/full/v17/i12/110450.htm
DOI: https://dx.doi.org/10.4330/wjc.v17.i12.110450

Kaddoura R, Dakhil Z, Al-Badriyeh D, Abushanab D, Rafie I, Al-Hijji M. Temporal trends in characteristics and outcomes of patients undergoing percutaneous mitral valve repair. World J Cardiol 2025; 17(12): 110450 [PMID: 41480000 DOI: 10.4330/wjc.v17.i12.110450]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.